AlphAIAlphAI — Financial news for AI agents
scanx.tradeOCT 283 min read$BHC

Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion

Bausch Health reported a 32% YoY increase in adjusted EBITDA to $1.305 billion for Q3FY26, exceeding $1 billion for the first time. The company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and cash flow, citing strong performance. Net debt was reduced by $521 million during the quarter. Salix segment drove growth with a 16% revenue increase, while Solta Medical saw reported revenue grow 18% but organic revenue decline 4%.

Original reporting
scanx.trade
Published Oct 28, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 2:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Bausch Health Q3FY26 Results: Adjusted EBITDA up 32% to $1.3 billion — source image
Source · scanx.trade
Decision brief

The 30-second read

$BHCBullishHigh
01

Why it matters

The earnings beat and guidance lift are likely to drive short‑term buying interest, especially in after‑hours trading.

02

Market read

First‑report earnings with material guidance upgrades; high relevance for traders targeting healthcare stocks.

03

What to watch

Tariff volatility in China could still pressure Solta Medical's organic growth despite reported revenue gains.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

Bausch Health Companies Inc. (NYSE:BHC) released its Q3 FY26 earnings, showing a 32% YoY increase in adjusted EBITDA and raising full‑year guidance.

Company-level read

Ticker impact

$BHCBullishHigh confidence
Context

Bausch Health reported Q3 FY26 adjusted EBITDA up 32% YoY and raised full-year 2026 revenue and EBITDA guidance.

Expected impact

upward pressure as investors price in higher revenue and EBITDA expectations

Evidence & confidence

The company beat internal benchmarks and lifted guidance by double‑digit percentages, a material catalyst for the stock.

Market effects

Sector

Improves outlook for the broader pharma/healthcare sector as a large generic drugmaker shows earnings momentum.

Regional

Positive for North American healthcare stocks, especially peers with exposure to generic drug pricing.

Global

Adds to global earnings momentum in the healthcare space, potentially influencing foreign investors tracking US pharma.

Counterpoint

What could challenge this read

The guidance raise may already be priced in; any miss on Q4 could trigger a pullback.

Key entities

  • company
    Bausch Health Companies Inc.

    US‑listed pharmaceutical company reporting Q3 FY26 results.

  • executive
    Thomas Appio

    CEO who highlighted disciplined capital allocation and announced share repurchase.

Read at source← All news

StoryBausch Health posts strong Q3 2026 results, raises full‑year outlook and launches $50 M buyback

Also covered by

4 outlets

Related articles

OCT 29
$BHCMedAI 8/10

What Bausch Health Cos (BHC) Said on Its Q3 Earnings Call

Bausch Health (BHC) reported Q3 revenue growth in international and Solta Medical segments, with Solta seeing 18% reported growth. The company reduced net debt by $521M in Q3 and announced a $50M share repurchase program. BHC updated its 2026 outlook, expecting 8% revenue growth and 13% adjusted EBITDA growth. Management remains focused on portfolio performance and operational improvements.

finance.yahoo.com2 min
OCT 28
$BHCHighAI 8/10

[Bausch Health Companies Q3 2026 Earnings Call] Bausch Health Raises Guidance Again as Quarterly Adjusted EBITDA Tops $1 Billion for First Time; Warns of $400–$500 Million XIFAXAN Headwind in 2027

Bausch Health (BHC) reported Q3 2026 revenue of $2.94B, up 10% YoY, with adjusted EBITDA surpassing $1B for the first time. The company raised full-year guidance but warned of $400M-$500M XIFAXAN headwind in 2027 due to Medicare rebates. Salix segment grew 16%, driven by XIFAXAN. Net debt reduced by $1B YTD, with plans for debt redemptions and share repurchases.

finance.biggo.com3 min